AstraZeneca study forecasts 16.5% population affected by chronic kidney disease by 2032
AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.